Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Accured Expenses (2016 - 2025)

Catalyst Pharmaceuticals' Change in Accured Expenses history spans 16 years, with the latest figure at $5.2 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 41.46% year-over-year to $5.2 million; the TTM value through Dec 2025 reached $24.2 million, down 55.13%, while the annual FY2025 figure was $24.2 million, 55.13% down from the prior year.
  • Change in Accured Expenses reached $5.2 million in Q4 2025 per CPRX's latest filing, down from $13.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $20.0 million in Q3 2024 to a low of -$7.0 million in Q1 2021.
  • Average Change in Accured Expenses over 5 years is $5.3 million, with a median of $5.8 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: crashed 316.77% in 2023, then surged 449.88% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $6.4 million in 2021, then skyrocketed by 78.78% to $11.5 million in 2022, then dropped by 28.82% to $8.2 million in 2023, then increased by 8.67% to $8.9 million in 2024, then plummeted by 41.46% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Change in Accured Expenses are $5.2 million (Q4 2025), $13.2 million (Q3 2025), and $8.3 million (Q2 2025).